A chiral supramolecular nanocatcher prepared by d-biotin-pillar[5]arene for the selective capture and targeted delivery of oxaliplatin enantiomers

Chiral anticancer drugs are the subject of ongoing research due to their optical characterization and pharmacological effects. Achieving a single enantiomer of a chiral anticancer drug is arduous, but it can significantly improve its pharmacokinetics for tumor therapy. Here, the chiral nanocatchers, known as d-biotin-P5⊃MCC NCs, were designed and prepared based on host-guest self-assembly between d-biotin anchored pillar[5]arene (d-biotin-P5) and myristoyl chloride choline (MCC). d-Biotin-P5⊃MCC NCs featuring the chiral separation and enzyme-induced disassemble were evaluated for their ability to selectively capture and subsequently target the release of (R,R)-OXA enantiomers into tumor cells. Furthermore, the use of d-biotin-P5⊃MCC NCs has demonstrated a significant enhancement in the intracellular uptake of OXA, with the drug being efficiently released to MCF-7 breast cancer cells. This has led to a superior inhibitory effect on MCF-7 cells when compared to free OXA, while also reducing the cytotoxicity of the drug in HEK 293 human embryonic kidney cells. This research not only paves a promising way for the fabrication of chiral supramolecular nanocarriers but also holds the potential to improve the processes of chiral drug separation and targeted therapy.